A new antibiotic drug, PP353, is being developed by Persica Pharmaceuticals and may provide significant relief for the 25% of people suffering from lower back pain due to infection. An early trial with 44 participants showed that 60% experienced major improvements in their pain and disability levels. If approved, this treatment could transform chronic lower back pain management by allowing patients to avoid long-term medications and surgeries. However, further trials are necessary for regulatory approval before availability to patients.
Dr. Shiva Tripathi emphasized that if the new drug PP353 is approved, it could significantly transform the management of chronic lower back pain for a substantial patient population.
The trial demonstrated that 60% of participants experienced major relief from back pain, marking a potential breakthrough in treatment options for those suffering from infection-related pain.
Collection
[
|
...
]